title: Initial treatment costs of organ-confined prostate cancer: a general perspective.
abstract: With the increasing prevalence of prostate cancer and evolving methods for the definitive treatment of OCPCa, health economic analyses will be critically important, albeit difficult to carry out. Preliminary studies point to RPP as the most cost-effective treatment for OCPCa. The quickest postoperative recovery, in experienced hands, occurs in RARP and RPP, with ORPP having a slightly, but statistically in significant, shorter hospital stay. It should be stressed that initial treatment costs are not the only important factor in healthcare costs. Readmission for early and late complications and the loss of productivity resulting from variation in time to return to work, need also to be considered. Loss of productivity may also vary in cost between different institutions and countries depending upon the proportion of patients employed. Further large-scale multicentre studies are necessary to assess this.
authors.affiliation: Urology Centre, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. sashurol@gmail.com
authors.forename: Sashi S
authors.initials: SS
authors.lastname: Kommu
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Eden
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Luscombe
authors.forename: Anurag
authors.initials: A
authors.lastname: Golash
authors.forename: Rajendra A
authors.initials: RA
authors.lastname: Persad
mesh_terms: D003362:Cost-Benefit Analysis; D017679:Cryotherapy / Q000191:economics*; D006801:Humans; D008297:Male; D011468:Prostatectomy / Q000191:economics*; D011471:Prostatic Neoplasms / Q000191:economics / Q000628:therapy*; D011878:Radiotherapy / Q000191:economics*